BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) Fundamental Analysis & Valuation

FRA:BIO3 • DE0005227235

30 EUR
0 (0%)
Last: May 23, 2025, 01:53 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership

This BIO3.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

4

Taking everything into account, BIO3 scores 4 out of 10 in our fundamental rating. BIO3 was compared to 75 industry peers in the Biotechnology industry. Both the profitability and the financial health of BIO3 get a neutral evaluation. Nothing too spectacular is happening here. BIO3 has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

4

1. BIO3.DE Profitability Analysis

1.1 Basic Checks

  • In the past year BIO3 has reported negative net income.
  • BIO3 had a positive operating cash flow in the past year.
  • In multiple years BIO3 reported negative net income over the last 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: BIO3 reported negative operating cash flow in multiple years.
BIO3.DE Yearly Net Income VS EBIT VS OCF VS FCFBIO3.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M 150M

1.2 Ratios

  • BIO3's Return On Assets of -1.73% is fine compared to the rest of the industry. BIO3 outperforms 68.49% of its industry peers.
  • The Return On Equity of BIO3 (-4.81%) is better than 69.86% of its industry peers.
  • The Return On Invested Capital of BIO3 (0.54%) is better than 76.71% of its industry peers.
Industry RankSector Rank
ROA -1.73%
ROE -4.81%
ROIC 0.54%
ROA(3y)2.71%
ROA(5y)-0.12%
ROE(3y)7.23%
ROE(5y)-0.54%
ROIC(3y)N/A
ROIC(5y)N/A
BIO3.DE Yearly ROA, ROE, ROICBIO3.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 30

1.3 Margins

  • BIO3 has a Operating Margin of 1.87%. This is in the better half of the industry: BIO3 outperforms 76.71% of its industry peers.
  • BIO3's Operating Margin has improved in the last couple of years.
  • BIO3 has a Gross Margin of 23.19%. This is comparable to the rest of the industry: BIO3 outperforms 53.42% of its industry peers.
  • BIO3's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 1.87%
PM (TTM) N/A
GM 23.19%
OM growth 3YN/A
OM growth 5Y99.04%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y25.34%
GM growth 5Y0.06%
BIO3.DE Yearly Profit, Operating, Gross MarginsBIO3.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 30 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. BIO3.DE Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BIO3 is destroying value.
  • The number of shares outstanding for BIO3 remains at a similar level compared to 1 year ago.
  • BIO3 has about the same amout of shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, BIO3 has an improved debt to assets ratio.
BIO3.DE Yearly Shares OutstandingBIO3.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
BIO3.DE Yearly Total Debt VS Total AssetsBIO3.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

2.2 Solvency

  • An Altman-Z score of 2.04 indicates that BIO3 is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • With a decent Altman-Z score value of 2.04, BIO3 is doing good in the industry, outperforming 65.75% of the companies in the same industry.
  • BIO3 has a debt to FCF ratio of 46.44. This is a negative value and a sign of low solvency as BIO3 would need 46.44 years to pay back of all of its debts.
  • With a decent Debt to FCF ratio value of 46.44, BIO3 is doing good in the industry, outperforming 78.08% of the companies in the same industry.
  • A Debt/Equity ratio of 1.26 is on the high side and indicates that BIO3 has dependencies on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 1.26, BIO3 is doing worse than 60.27% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.26
Debt/FCF 46.44
Altman-Z 2.04
ROIC/WACC0.09
WACC5.93%
BIO3.DE Yearly LT Debt VS Equity VS FCFBIO3.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

  • BIO3 has a Current Ratio of 4.93. This indicates that BIO3 is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Current ratio value of 4.93, BIO3 is doing good in the industry, outperforming 79.45% of the companies in the same industry.
  • A Quick Ratio of 1.66 indicates that BIO3 should not have too much problems paying its short term obligations.
  • BIO3 has a Quick ratio of 1.66. This is comparable to the rest of the industry: BIO3 outperforms 46.58% of its industry peers.
Industry RankSector Rank
Current Ratio 4.93
Quick Ratio 1.66
BIO3.DE Yearly Current Assets VS Current LiabilitesBIO3.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. BIO3.DE Growth Analysis

3.1 Past

  • BIO3 shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -117.24%.
  • The Revenue for BIO3 has decreased by -15.85% in the past year. This is quite bad
  • BIO3 shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.62% yearly.
EPS 1Y (TTM)-117.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-173.33%
Revenue 1Y (TTM)-15.85%
Revenue growth 3Y12.09%
Revenue growth 5Y11.62%
Sales Q2Q%-42.29%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y1600%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year11.95%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BIO3.DE Yearly Revenue VS EstimatesBIO3.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M
BIO3.DE Yearly EPS VS EstimatesBIO3.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2020 2021 2022 2024 2025 0 1 -1

More info and screens

Find the best growth stocksShow best growing peers

4

4. BIO3.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • BIO3 reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Based on the Price/Forward Earnings ratio of 19.80, the valuation of BIO3 can be described as rather expensive.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of BIO3 indicates a rather cheap valuation: BIO3 is cheaper than 86.30% of the companies listed in the same industry.
  • BIO3 is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 25.11, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 19.8
BIO3.DE Price Earnings VS Forward Price EarningsBIO3.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BIO3 indicates a somewhat cheap valuation: BIO3 is cheaper than 75.34% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, BIO3 is valued a bit cheaper than the industry average as 79.45% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 82.44
EV/EBITDA 33.87
BIO3.DE Per share dataBIO3.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • BIO3's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. BIO3.DE Dividend Analysis

5.1 Amount

  • With a yearly dividend of 0.09%, BIO3 is not a good candidate for dividend investing.
  • Compared to an average industry Dividend Yield of 0.62, BIO3 pays a better dividend. On top of this BIO3 pays more dividend than 90.41% of the companies listed in the same industry.
  • With a Dividend Yield of 0.09, BIO3 pays less dividend than the S&P500 average, which is at 1.82.
Industry RankSector Rank
Dividend Yield 0.09%

5.2 History

  • On average, the dividend of BIO3 grows each year by 14.87%, which is quite nice.
Dividend Growth(5Y)14.87%
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

  • The dividend of BIO3 is growing, but earnings are growing more, so the dividend growth is sustainable.
DPN/A
EPS Next 2YN/A
EPS Next 3YN/A
BIO3.DE Yearly Income VS Free CF VS DividendBIO3.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M 150M

More info and screens

Find the best dividend stocksShow peers with best dividend

BIO3.DE Fundamentals: All Metrics, Ratios and Statistics

BIOTEST AG-VORZUGSAKTIEN

FRA:BIO3 (5/23/2025, 1:53:46 PM)

30

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12
Earnings (Next)08-04
Inst Owners0.21%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap1.19B
Revenue(TTM)635.20M
Net Income(TTM)-24.50M
Analysts45.71
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.09%
Yearly Dividend0.04
Dividend Growth(5Y)14.87%
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 19.8
P/S 1.87
P/FCF 82.44
P/OCF 82.44
P/B 2.33
P/tB 2.41
EV/EBITDA 33.87
EPS(TTM)-0.65
EYN/A
EPS(NY)1.52
Fwd EY5.05%
FCF(TTM)0.36
FCFY1.21%
OCF(TTM)0.36
OCFY1.21%
SpS16.05
BVpS12.88
TBVpS12.47
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -1.73%
ROE -4.81%
ROCE 0.95%
ROIC 0.54%
ROICexc 0.56%
ROICexgc 0.57%
OM 1.87%
PM (TTM) N/A
GM 23.19%
FCFM 2.27%
ROA(3y)2.71%
ROA(5y)-0.12%
ROE(3y)7.23%
ROE(5y)-0.54%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y111.24%
ROICexc growth 3YN/A
ROICexc growth 5Y111.29%
OM growth 3YN/A
OM growth 5Y99.04%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y25.34%
GM growth 5Y0.06%
F-Score3
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 1.26
Debt/FCF 46.44
Debt/EBITDA 12.19
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 0.82
Cash Conversion 27.43%
Profit Quality N/A
Current Ratio 4.93
Quick Ratio 1.66
Altman-Z 2.04
F-Score3
WACC5.93%
ROIC/WACC0.09
Cap/Depr(3y)81.86%
Cap/Depr(5y)79.06%
Cap/Sales(3y)4.84%
Cap/Sales(5y)4.72%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-117.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-173.33%
EPS Next Y1600%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-15.85%
Revenue growth 3Y12.09%
Revenue growth 5Y11.62%
Sales Q2Q%-42.29%
Revenue Next Year11.95%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-93.3%
EBIT growth 3YN/A
EBIT growth 5Y122.17%
EBIT Next Year825%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y114.72%
FCF growth 3Y27.05%
FCF growth 5YN/A
OCF growth 1Y114.72%
OCF growth 3Y21.56%
OCF growth 5YN/A

BIOTEST AG-VORZUGSAKTIEN / BIO3.DE FAQ

What is the ChartMill fundamental rating of BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) stock?

ChartMill assigns a fundamental rating of 4 / 10 to BIO3.DE.


Can you provide the valuation status for BIOTEST AG-VORZUGSAKTIEN?

ChartMill assigns a valuation rating of 4 / 10 to BIOTEST AG-VORZUGSAKTIEN (BIO3.DE). This can be considered as Fairly Valued.


How profitable is BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) stock?

BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) has a profitability rating of 4 / 10.


What is the financial health of BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) stock?

The financial health rating of BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) is 5 / 10.